UBS Group
SABS icon

UBS Group’s SAB Biotherapeutics SABS Stock Holding History

UBS Group’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43M Buy
365,878
+319,255
+685% +$1.19M ﹤0.01% 5417
2026
Q1 		$179K Buy
46,623
+39,225
+530% +$156K ﹤0.01% 6697
2025
Q4 		$27.7K Sell
7,398
-5,823
-44% -$19.2K ﹤0.01% 7578
2025
Q3 		$26.6K Buy
13,221
+2,563
+24% +$5.79K ﹤0.01% 7977
2025
Q2 		$18.7K Buy
10,658
+10,580
+13,564% +$17.5K ﹤0.01% 8491
2025
Q1 		$106 Sell
78
-1,005
-93% -$2.31K ﹤0.01% 9939
2024
Q4 		$4.11K Buy
+1,083
New +$3.56K ﹤0.01% 8789
2024
Q1 		– Sell
-50
Closed -$344 – 9924
2023
Q4 		$344 Buy
+50
New +$419 ﹤0.01% 8714
2023
Q2 		– Sell
-668
Closed -$2.94K – 9539
2023
Q1 		$2.94K Sell
668
-25
-4% -$158 ﹤0.01% 8414
2022
Q4 		$4.09K Buy
693
+543
+362% +$4.96K ﹤0.01% 9388
2022
Q3 		$1K Buy
150
+50
+50% +$496 ﹤0.01% 10021
2022
Q2 		$1K Sell
100
-41
-29% -$861 ﹤0.01% 9949
2022
Q1 		$6K Sell
141
-454
-76% -$21K ﹤0.01% 8987
2021
Q4 		$47K Buy
+595
New +$55.8K ﹤0.01% 6964
2021
Q3 		– Sell
-148
Closed -$15K – 10003
2021
Q2 		$15K Buy
148
+61
+70% +$6.05K ﹤0.01% 7647
2021
Q1 		$9K Buy
+87
New +$8.7K ﹤0.01% 8019

Other funds holding SABS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

UBS Group's SABS Position: Q2 2026 in Review

UBS Group increased its SAB Biotherapeutics (SABS) stake by 685% in Q2 2026, buying an estimated $1.19M and bringing the position to 365,878 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #5417.

UBS Group first reported a position in SABS in Q1 2021 and has held it in 16 quarters since. 46 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • UBS Group held 365,878 shares of SAB Biotherapeutics worth $1.43M as of Q2 2026.
  • UBS Group bought 319,255 SAB Biotherapeutics shares in Q2 2026, an estimated $1.19M.
  • SAB Biotherapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5417 holding.
  • UBS Group first reported a position in SAB Biotherapeutics in Q1 2021 and has held it in 16 quarters since.
  • 46 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.